Journal of Clinical Oncology
Tamoxifen administered for 5 years at 20 mg/d is effective in breast cancer treatment and prevention, but toxicity has limited its broad use
Purpose: Five-year data of the phase III trial TAM-01 showed that low-dose tamoxifen at 5 mg once daily administered for 3 years in women with intraepithelial neoplasia (IEN) reduced by 52% the recurrence of invasive breast cancer or ductal carcinoma in situ (DCIS), without additional adverse events over placebo
6,26 Tamoxifen has an established effect, but uptake is low, particularly so in the preventive setting
Five-year data of the phase III trial TAM-01 showed that low-dose tamoxifen at 5 mg once daily administered for 3 years in women with intraepithelial neoplasia (IEN) reduced by 52% the recurrence of invasive breast cancer or ductal carcinoma in situ (DCIS), without additional adverse events over placebo
The double-blind study enrolled women aged between 40 and 74 years Will a Low-Dose Option Improve Uptake of Tamoxifen for Breast Cancer Risk Reduction? Will a Low-Dose Option Improve Uptake of Tamoxifen for Breast Cancer Risk Reduction? J Clin Oncol
Fabian said
Journal of Clinical Oncology
We hypothesized that a lower dose given for a shorter period could be as effective in preventing recurrence from breast intraepithelial both low dose and standard dose tamoxifen, more than 75% started low dose tamoxifen
5 The increase of menopausal symptoms during tamoxifen therapy, including vaso-motor symptoms and sexual and gynecologic distur-bances, is also a cause of decreased quality of of tamoxifen, including venous thromboembolic events and endometrial cancer, is a significant problem and may explain the low uptake of tamoxifen as preventive therapy
org by 40
Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Tamoxifen is recommended for these patients to reduce help reduce subsequent breast cancer risk, but a relatively low percentage of patients actually take it, often due to concerns about side effects
PATIENTS AND METHODS Women, 40-74 years of age, participating in the Swedish mammography low-dose tamoxifen is less likely to cause these serious adverse effects compared with full-dose therapy
5 The increase of menopausal symptoms during tamoxifen therapy, including vaso-motor symptoms and sexual and gynecologic distur-bances, is also a cause of decreased quality of Low-dose tamoxifen appears to be a particularly favorable choice that is well tolerated, without risk of serious adverse events and offers comparable risk reduction to other regimens
low-dose tamoxifen is less likely to cause these serious adverse effects compared with full-dose therapy
The research was published online March 18 in the Journal of Clinical Oncology
15_suppl
The authors assessed their combination in a two-by-two biomarker trial
23
Quick Links Low-Dose (5 mg) Versus Standard-Dose Tamoxifen A recent randomized trial in women with intra-epithelial neoplasia suggests that low-dose tamoxifen reduces risk of breast cancer relative to placebo, but there are no data on Mark R
Journal of Clinical Oncology 2007 25: 18_suppl, 1514-1514 View Options
5 The increase of menopausal symptoms during tamoxifen therapy, including vaso-motor symptoms and sexual and gynecologic distur-bances, is also a cause of decreased quality of The finding that low-dose tamoxifen favorably modulates both IGF-1 and mammographic breast density in women receiving combined hormone replacement therapy without significantly increasing hot flashes or endometrial proliferation is exciting and is grounds for further clinical study
9743 Journal of Clinical Oncology 25 Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 18 Mar 2021, 39(17): 1899-1908 DOI: 10
Relevance Tamoxifen prevents breast cancer in high-risk women and reduces mortality in the adjuvant setting but uptake is low because of severe side effects
6% of premenopausal and 26
The authors assessed their combination in a two-by-two biomarker trial
We assessed the optimal biologic dose and schedule of tamoxifen in HRT users using surrogate end point biomarkers and menopausal symptoms
Bonanni, B
If a low dose of tamoxifen is as effective as the standard 20 mg and causes fewer symptoms, it has the potential to improve
Five-year data of the phase III trial TAM-01 showed that low-dose tamoxifen at 5 mg once daily administered for 3 years in women with intraepithelial neoplasia (IEN) reduced by
Nine percent (n = 7) of patients on standard dose tamoxifen switched to low dose due to adverse effects including hot flashes, mood changes, and insomnia
Data on low-dose tamoxifen as an alternative to the standard dose for both pre- and postmenopausal women with intraepithelial neoplasia are discussed in the
Among premenopausal
, “looked at a low-dose tamoxifen (5 mg) versus placebo and found a 50% reduction in the incidence of breast cancer with this low dose
77
5 The increase of menopausal symptoms during tamoxifen therapy, including vaso-motor symptoms and sexual and gynecologic distur-bances, is also a cause of decreased
11
Mammographic density change is a proxy for tamoxifen therapy response
Relevance Tamoxifen prevents breast cancer in high-risk women and reduces mortality in the adjuvant setting but uptake is low because of severe side effects
The finding that low-dose tamoxifen favorably modulates both IGF-1 and mammographic breast density in women receiving combined hormone replacement therapy without significantly increasing hot flashes or endometrial proliferation is exciting and is grounds for further clinical study
The 5 mg dose of tamoxifen (named ‘baby-TAM’ by the investigators) was shown to be more effective in postmenopausal women, in those with low-baseline estradiol (<15
Volume In conclusion, low-dose tamoxifen given for 3 years is effective in women with preinvasive disease and provides a valid and potentially safer alternative to full-dose tamoxifen, as indicated by the new ASCO guidelines for breast cancer risk reduction
2005
00656
Free to read & use If low-dose tamoxifen retains its preventive effect with fewer and less severe symptoms, it has the potential to increase
The low toxicity of low-dose tamoxifen is confirmed by the same adherence in both arms compared with the full dose where adherence was 10% lower in the tamoxifen arm mostly because of menopausal symptoms
To the best of our knowledge, this is the first report on the
Several reasons point to why women might decline tamoxifen or other types of endocrine therapy for breast cancer risk reduction
Low-dose tamoxifen can reduce mammographic breast density and may promote higher uptake in women at elevated risk for breast cancer
23